Trial Profile
A Randomized, Double-blind, Placebo-controlled Multi-center Study of GB-0998 for Treatment of Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2014
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Sponsors Benesis Corporation
- 24 Dec 2014 New trial record